NDAORALTABLET
Approved
May 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PMB 400 is an oral tablet combining conjugated estrogens with meprobamate, a fixed-dose combination approved in 1957 for menopausal symptom management. The estrogen component addresses vasomotor symptoms while meprobamate provides anxiolytic support. This product represents a legacy combination therapy from the mid-20th century.
LOE Approaching
Minimal commercial investment expected as product approaches loss of exclusivity with likely small field team focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PMB 400 offers limited career growth potential with zero linked job openings and a product in clear decline. Roles available focus on product maintenance, compliance, and managed care rather than commercial expansion or innovation.
Brand Manager (Legacy Products)Customer Service Specialist
Worked on PMB 400 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.